New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 24, 2014
06:06 EDTSRPT, APCStocks with implied volatility below IV index mean; APC SRPT
Stocks with implied volatility below IV index mean; Anadarko (APC) 25, Sarepta (SRPT) 72 according to iVolatility.
News For APC;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 25, 2015
13:57 EDTSRPTUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 23, 2015
10:02 EDTSRPTOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 22, 2015
16:15 EDTSRPTSarepta initiated with a Sector Perform at RBC Capital
Subscribe for More Information
January 21, 2015
10:01 EDTSRPTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:59 EDTSRPTSarepta downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
January 20, 2015
07:29 EDTAPCAnadarko upgraded to Buy from Accumulate at KLR Group
Subscribe for More Information
January 18, 2015
18:11 EDTAPCAnadarko faces pollution penalty in Deepwater Horizon disaster, WSJ says
Subscribe for More Information
January 16, 2015
10:01 EDTAPCOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAPCAnadarko upgraded to Overweight from Neutral at Atlantic Equities
Subscribe for More Information
January 15, 2015
15:26 EDTSRPTSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
07:13 EDTSRPTJPMorgan to hold a conference
Subscribe for More Information
January 14, 2015
08:30 EDTSRPTSarepta says first patient dosed in European Phase 1/II SRP-4053 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use